NCT02519036: A reported trial by Ionis Pharmaceuticals, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02519036 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 6, 2015 |
| Completion date | Nov. 8, 2017 |
| Required reporting date | Nov. 8, 2020, midnight |
| Actual reporting date | May 6, 2019 |
| Date last checked at ClinicalTrials.gov | Sept. 16, 2025 |
| Days late | None |